logo-loader

Northland Capital Partners View on the City - ImmuPharma

Published: 09:39 02 Nov 2017 GMT

no_picture_pai

IMMUPHARMA (LON:IMM)
SECTOR – HEALTHCARE
RATING – BUY*
MARKET CAP – £127m
CURRENT PRICE – 95p#
TARGET PRICE – 181p
ANALYST – Vadim Alexandre
  Year-end Dec 2015A 2016A 2017E 2018E
  Revenue (£m) 0.1 0.2 - 32.5
  EBITDA (£m) - - - -
  Adj. pre-tax Profit (£m) (4.5) (6.3) (4.9) 26.6
  Adj. EPS (p) (4.4) (4.5) (3.1) 19.71
  DPS (p) - - - -
  P/E (x) - - - -
  Dividend yield (%) - - - -
  EV/EBITDA (x) - - - -
     
 
SOURCE: Northland Capital Partners Limited estimates. Priced at prior day market close. *Northland Capital Partners acts as Nomad and Broker to ImmuPharma and therefore this information should be viewed as a Marketing Communication.

Lupuzor trial update

NORTHLAND VIEW
  ImmuPharma issued an update on its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential treatment of Lupus.
  Key highlights included:
  200 patients were successfully recruited and randomised (dosed)
  all patients in the study have passed the 9 months stage
  116 patients (58%) have completed the full 12 months of the study

Lupuzor is progressing well through its pivotal Phase III trial. The drug continues to demonstrate a strong safety profile. The study is on track to report top line results in Q1-2018. Should Lupuzor successfully meet the trial endpoints, we estimate that ImmuPharma’s shares would significantly rerate to the upside.

COMPANY DESCRIPTION
ImmuPharma PLC is a late clinical stage drug development business specialising in the area of autoimmune disease.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

2 hours, 34 minutes ago